1964 Pilot study of bevacizumab (Bev) in combination with docetaxel (T) and cyclophosphamide (C) as adjuvant treatment (AdjRx) for patients (pts) with early stage (ES) HER-2 normal breast cancer (BrCa) ICORG 08-10. (September 2015) - Gullo, G.; Kennedy, J.; Breathnach, O.; McCaffrey, J.; Keane, M.; Martin, M.; Gupta, R.; Leonard, G.; Calvert, P.; Donnellan, P.; Walshe, J.; Mc Dermott, E.; et al.